Total Valuation
Daewon Pharmaceutical Co., Ltd has a market cap or net worth of ₩157.86B. The enterprise value is $371.66K.
Market Cap₩157.86B
Enterprise Value$371.66K
Share Statistics
Daewon Pharmaceutical Co., Ltd has 22,427,584 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding22,427,584
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Daewon Pharmaceutical Co., Ltd’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is -0.49%.
Return on Equity (ROE)>-0.01
Return on Assets (ROA)>-0.01
Return on Invested Capital (ROIC)-0.49%
Return on Capital Employed (ROCE)<0.01
Revenue Per Employee480.66M
Profits Per Employee340.38K
Employee Count1,260
Asset Turnover0.99
Inventory Turnover3.47
Valuation Ratios
The current PE Ratio of Daewon Pharmaceutical Co., Ltd is ―. Daewon Pharmaceutical Co., Ltd’s PEG ratio is 1.69.
PE Ratio―
PS Ratio0.42
PB Ratio0.96
Price to Fair Value0.96
Price to FCF18.59
Price to Operating Cash Flow3.84
PEG Ratio1.69
Income Statement
In the last 12 months, Daewon Pharmaceutical Co., Ltd had revenue of 605.64B and earned -1.38B in profits. Earnings per share was -64.37.
Revenue605.64B
Gross Profit266.09B
Operating Income3.48B
Pretax Income2.75B
Net Income-1.38B
EBITDA27.23B
Earnings Per Share (EPS)-64.37
Cash Flow
In the last 12 months, operating cash flow was 41.82B and capital expenditures -32.58B, giving a free cash flow of 9.24B billion.
Operating Cash Flow41.82B
Free Cash Flow9.24B
Free Cash Flow per Share412.14
Dividends & Yields
Daewon Pharmaceutical Co., Ltd pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.01
52-Week Price Change-43.20%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
Daewon Pharmaceutical Co., Ltd upcoming earnings date is Aug 18, 2026, TBA (Confirmed).
Last Earnings DateMay 15, 2026
Next Earnings DateAug 18, 2026
Ex-Dividend Date―
Financial Position
Daewon Pharmaceutical Co., Ltd as a current ratio of 1.19, with Debt / Equity ratio of 70.46%
Current Ratio1.19
Quick Ratio0.73
Debt to Market Cap0.71
Net Debt to EBITDA5.14
Interest Coverage Ratio0.48
Taxes
In the past 12 months, Daewon Pharmaceutical Co., Ltd has paid 4.75B in taxes.
Income Tax4.75B
Effective Tax Rate1.73
Enterprise Valuation
Daewon Pharmaceutical Co., Ltd EV to EBITDA ratio is 14.55, with an EV/FCF ratio of 28.74.
EV to Sales0.65
EV to EBITDA14.55
EV to Free Cash Flow28.74
EV to Operating Cash Flow9.09
Balance Sheet
Daewon Pharmaceutical Co., Ltd has ₩56.01B in cash and marketable securities with ₩185.21B in debt, giving a net cash position of -₩129.20B billion.
Cash & Marketable Securities₩56.01B
Total Debt₩185.21B
Net Cash-₩129.20B
Net Cash Per Share-₩5.76K
Tangible Book Value Per Share₩10.07K
Margins
Gross margin is 44.55%, with operating margin of 0.58%, and net profit margin of -0.23%.
Gross Margin44.55%
Operating Margin0.58%
Pretax Margin0.45%
Net Profit Margin-0.23%
EBITDA Margin4.50%
EBIT Margin0.58%
Analyst Forecast
The average price target for Daewon Pharmaceutical Co., Ltd is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast1.33%
EPS Growth Forecast-142.09%